A medication to treat Type 2 diabetes has significantly reduced blood sugar and body weight in participants of a late-phase clinical trial.
Eli Lilly’s Tirzepatide is in phase 3 development for blood glucose management in adults with Type 2 diabetes and for chronic weight management. It is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure, therefore, resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight.
Find out more HERE.
